Abstract
Background Microbial cultures for the diagnosis of pneumonia take several days to return a result, and are frequently negative, compromising antimicrobial stewardship. The objective of this study was to establish the performance of a syndromic molecular diagnostic approach, using a custom TaqMan array card (TAC) covering 52 respiratory pathogens, and assess its impact on antimicrobial prescribing.
Methods The TAC was validated against a retrospective multi-centre cohort of broncho-alveolar lavage samples. The TAC was assessed prospectively in patients undergoing investigation for suspected pneumonia, with a comparator cohort formed of patients investigated when the TAC laboratory team were unavailable.
Co-primary outcomes were sensitivity compared to conventional microbiology and, for the prospective study, time to result. Metagenomic sequencing was performed to validate findings in prospective samples. Antibiotic free days (AFD) were compared between the study cohort and comparator group.
Results 128 stored samples were tested, with sensitivity of 97% (95% CI 88-100%). Prospectively 95 patients were tested by TAC, with 71 forming the comparator group. TAC returned results 51 hours (IQR 41-69 hours) faster than culture and with sensitivity of 92% (95% CI 83-98%) compared to conventional microbiology. 94% of organisms identified by sequencing were detected by TAC. There was a significant difference in the distribution of AFDs with more AFDs in the TAC group (p=0.02). TAC group were more likely to experience antimicrobial de-escalation (OR 2.9 (95%1.5-5.5).
Conclusions Implementation of a syndromic molecular diagnostic approach to pneumonia led to faster results, with high sensitivity and impact on antibiotic prescribing.
Trial registration The prospective study was registered with clinicaltrials.gov NCT03996330
Competing Interest Statement
MDC is the inventor on a patent held by the Secretary of State for Health (UK Government) EP2788503, which covers some of the genetic sequences used in this study. VN is a founder, Director and shareholder in Cambridge Infection Diagnostics Ltd (CID Ltd) which is a commercial company aimed at developing molecular diagnostics in infection and antimicrobial and AMR stewardship. NMB, GD and ACM are members of the Scientific Advisory Board of Cambridge Infection Diagnostics Ltd (CID Ltd). All other authors declare no conflict of interest.
Clinical Trial
NCT03996330
Funding Statement
The study was funded by Addenbrookes Charitable Trust and the NIHR Cambridge Biomedical Resource Centre (Grant 18135 to Professor Dougan). Dr Torok is supported by a Clinician Scientist Fellowship (funded by the Academy of Medical Sciences and the Health Foundation) and by the NIHR Biomedical Research Centre. Dr Conway Morris was supported by a Clinical Research Career Development Fellowship from the Wellcome Trust at the time of the work (WT 2055214/Z/16/Z) and is currently supported by an MRC Clinician Scientist Fellowship (MR/V006118/1). The metagenomic sequencing was funded by the Wellcome Trust. VAP-Rapid was funded Health Innovation Challenge Fund(HICF-510-078-094949/Z/10/X) a parallel funding partnership between the UK Department of Health and Wellcome Trust. Professor Simpson is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health or Wellcome Trust. The funders had no role in the analysis of data or decision to publish. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from patients or their proxy decision maker for studies where samples were obtained, where participants regained capacity retrospective consent was sought. The samples for the retrospective study were obtained from the VAP-Rapid study (ref 15) which was approved by the England and Northern Ireland (13/LO/065) and Scotland (13/SS/0074) National Research Ethics Service committees and sponsored by Newcastle upon Tyne Hospitals NHS Foundation Trust. The prospective study was approved by the Leeds East Research Ethics Committee (17/YH/0286) Cambridge University Hospitals NHS Foundation Trust was the sponsor. The assessment of routinely collected data from the comparator group received a consent waiver and was conducted under a protocol approved by the institutional review board (A095506).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations Ethical approval and consent to participate: Written informed consent was obtained from patients or their proxy decision maker for studies where samples were obtained, where participants regained capacity retrospective consent was sought. The samples for the retrospective study were obtained from the VAPrapid study (ref 15) which was approved by the England and Northern Ireland (13/LO/065) and Scotland (13/SS/0074) National Research Ethics Service committees and sponsored by Newcastle upon Tyne Hospitals NHS Foundation Trust.
The prospective study was approved by the Leeds East Research Ethics Committee (17/YH/0286) Cambridge University Hospitals NHS Foundation Trust was the sponsor. The assessment of routinely collected data from the comparator group received a consent waiver and was conducted under a protocol approved by the institutional review board (A095506).
Consent for publication: no individual patient data presented, not required
Availability of data: Microbial sequencing data is available from European Nucleotide Archive (ENA) with study accession numbers ERP111277, ERP111280, ERP112277, and ERP018622. Patient data is not publicly available for confidentiality reasons, but anonymised data can be obtained through contact with the corresponding author, subject to appropriate data sharing agreements being in place.
Competing interests: MDC is the inventor on a patent held by the Secretary of State for Health (UK Government) EP2788503, which covers some of the genetic sequences used in this study. VN is a founder, Director and shareholder in Cambridge Infection Diagnostics Ltd (CID Ltd) which is a commercial company aimed at developing molecular diagnostics in infection and antimicrobial and AMR stewardship. NMB, GD and ACM are members of the Scientific Advisory Board of Cambridge Infection Diagnostics Ltd (CID Ltd). All other authors declare no conflict of interest.
Funding The study was funded by Addenbrooke’s Charitable Trust and the NIHR Cambridge Biomedical Resource Centre (Grant 18135 to Professor Dougan). Dr Török is supported by a Clinician Scientist Fellowship (funded by the Academy of Medical Sciences and the Health Foundation) and by the NIHR Biomedical Research Centre. Dr Conway Morris was supported by a Clinical Research Career Development Fellowship from the Wellcome Trust at the time of the work (WT 2055214/Z/16/Z) and is currently supported by an MRC Clinician Scientist Fellowship (MR/V006118/1). The metagenomic sequencing was funded by the Wellcome Trust. VAPrapid was funded Health Innovation Challenge Fund(HICF-510-078;094949/Z/10/X), a parallel funding partnership between the UK Department of Health and Wellcome Trust. Professor Simpson is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health or Wellcome Trust. The funders had no role in the analysis of data or decision to publish. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
VN -Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.
JBS -resources, investigation, data curation, formal analysis, writing-original draft.
MM-resources, investigation, writing-review and editing.
TH-resources, investigation, writing-review and editing
EH-investigation, writing-review and editing.
SF-investigation, writing-review and editing.
JD-investigation, writing-review and editing.
SP-investigation, writing-review and editing.
EHH-investigation, writing-review and editing.
PP-investigation, data curation writing-review and editing.
JB-investigation, data curation writing-review and editing.
LT-investigation, data curation writing-review and editing.
WS- data curation writing-review and editing
JS- resources, investigation, writing-review and editing
AR- resources, investigation, writing-review and editing
MR-data curation writing-review and editing.
DS-data curation writing-review and editing.
MET-conceptualisation, investigation, data curation writing-review and editing
DE-investigation, writing-review and editing.
VW-formal analysis, investigation, data curation writing-review and editing.
MDC-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.
NB-Conceptualisation, resources, investigation, writing-review and editing, project administration, supervision. AJS- resources, investigation, writing-review and editing
JH-Conceptualisation, resources, investigation, writing-review and editing.
GD-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.
ACM-Conceptualisation, methodology, resources, investigation, writing-original draft, project administration, formal analysis, funding acquisition, supervision.
Additional data added regarding validation of TAC in a cohort of stored samples from the VAPrapid trial (table 1, methods and results, supplemental data), further analysis of antibiotic changes in the prospective and comparator cohorts (table 4 and supplemental section)
Data Availability
De-identified data is available on request to the corresponding author. All samples were sequenced at the Wellcome Sanger Institute, and raw read data is available at the European Nucleotide Archive (ENA) with study accession numbers ERP111277, ERP111280, ERP112277, and ERP018622.
